Fisher & Paykel HealthcareASX:FPH +0.13%88 Gross Margin % is 63.94% as of Mar. 2026, which is 1% above its 10-year median of 63.22. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 68.7% on this metric.
ASX:FPH's Gross Margin % is ranked better than 68.7% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs ASX:FPH: 63.69
Fisher & Paykel Healthcare had a gross margin of 63.94% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Fisher & Paykel Healthcare had a gross margin of 63.94% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Fisher & Paykel Healthcare Gross Margin % Related Terms
Fisher & Paykel Healthcare Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:FPH vs ISRG, BDX, MDLN: Gross Margin % Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Fisher & Paykel Healthcare (ASX:FPH) has a Gross Margin % of 63.94% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 63.22. Over the past decade, Fisher & Paykel Healthcare's Gross Margin % has ranged from 41.41 to 66.92. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #252 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 31.3%.
Is Fisher & Paykel Healthcare's Gross Margin % too high?
Fisher & Paykel Healthcare's current Gross Margin % of 63.94% is near median its 10-year median of 63.22. Over the past 10 years, this metric has ranged from a low of 41.41 to a high of 66.92. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Fisher & Paykel Healthcare's value of 63.94% is 22.8% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #252 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Gross Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #252 out of 805 companies for Gross Margin %. This puts Fisher & Paykel Healthcare in the upper half of its industry. The industry median Gross Margin % is 52.07. Fisher & Paykel Healthcare's value of 63.94% is 22.8% above this benchmark. Historically, Fisher & Paykel Healthcare's own Gross Margin % has ranged from 41.41 to 66.92 over the past decade. While the company's 10-year median is 63.22 vs. the industry median of 52.07, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Gross Margin % of 63.94% is 22.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Gross Margin % is 63.94%, which is near median its own 10-year median of 63.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.31, compared to a current price of A$31.57 — trading 13.1% below its estimated fair value. The current Gross Margin % is 63.94%, which is near median its 10-year median of 63.22 and 22.8% above the Medical Devices & Instruments industry median of 52.07. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Gross Margin % is 63.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$31.57 is trading 13.1% below its estimated GF Value™ of A$36.31.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:FPH:
Gross Margin %: 63.94% (near median its 10-year median of 63.22)
GF Value™: A$36.31 vs. price of A$31.57 (13.1% below fair value)
Industry Position: 22.8% above the Medical Devices & Instruments median (#252 of 805)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score
Get the complete analysis for ASX:FPH
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
